Read more
6:02 PM · 11 January 2022

US orders more doses of COVID treatment from VIR Biotechnology

-
-
Open account Download free app
-
-
Open account Download free app

Vir Biotechnology (VIR.US) announced today that the US government will buy an additional 600,000 doses of sotrovimab, its Covid-19 treatment developed together with British partner GlaxoSmithKline (GSK.UK). The extra doses will be delivered in the first quarter of 2022 to the US, which has an option to purchase more in the second quarter. 

Including today's announcement, the two companies have agreements for the sale of roughly 1.7 million doses of sotrovimab worldwide. Sotrovimab was granted emergency use authorization by the Food and Drug Administration in May 2021 for treatment of mild to moderate COVID-19 in at-risk adults and children 12 and older. Preclinical data has shown treatment is effective against all COVID-19 variants, including delta and omicron. 

Vir Biotechnology (VIR.US) stock rose nearly 9.0% in premarket, however later in the session bullish momentum faded away. Buyers failed to break above the local resistance zone at $35.30 which is marked with 78.6% Fibonacci retracement of the last upward wave and price pulled back to recent lows at $32.25. Source: xStation5

20 January 2026, 9:30 PM

Netflix down 5% after Q4 results 📉 Is Wall Street turning bearish?

20 January 2026, 6:54 PM

Daily Summary: "Sell America" pushes US assets off the cliff (20.01.2026)

20 January 2026, 3:21 PM

Banks fear Trump📉Central planning in the USA?

20 January 2026, 2:05 PM

Earnings are rising, risk is under control. U.S. Bancorp shows real class 📈

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits